Progressive Resistance Training and Cancer Testis (PROTRACT) - Efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: Design of a randomized controlled trial

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Christensen, Jesper F ^a   Andersen, Jesper L ^b,c   Adamsen, Lis ^a   Lindegaard, Birgitte ^a   Mackey, Abigail L ^b,c   Nielsen, Rie H ^b,c   Rørth, Mikael ^a   Daugaard, Gedske ^a  

^a Copenhagen University Hospital ^*  (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Muscle morphology; Resistance exercise; Testicular canceranti neoplasms

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; MESSENGER RNA; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BODY COMPOSITION; CANCER PATIENT; GENE EXPRESSION; GLUCOSE METABOLISM; HIGH INTENSITY PROGRESSIVE RESISTANCE TRAINING; HISTOCHEMISTRY; HUMAN; INFLAMMATION; LIPID METABOLISM; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE CONTRACTION; MUSCLE FUNCTION; MUSCLE STRENGTH; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN METABOLISM; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; SATELLITE CELL; SHORT FORM 36; SKELETAL MUSCLE; TESTIS CANCER; TREATMENT RESPONSE; VOLUNTARY MOVEMENT; WHOLE BODY SCINTISCANNING; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; METHODOLOGY; MUSCLE WEAKNESS; REPRODUCIBILITY; TESTIS TUMOR;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BLEOMYCIN; CASE-CONTROL STUDIES; CISPLATIN; ETOPOSIDE; HUMANS; MALE; MUSCLE WEAKNESS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RESISTANCE TRAINING; TESTICULAR NEOPLASMS;

EID: 79960861714     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-326     Document Type: Article

References (54)

1. Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International patterns and trends in testis cancer incidence. Int J Cancer 2005, 115:822-827. 10.1002/ijc.20931, 15704170.
2. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007, 8:784-796. 10.1016/S1470-2045(07)70246-2, 17714993.
3. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010, 102:1114-1130. 10.1093/jnci/djq216, 2914759, 20585105.
4. Orre IJ, Fossa SD, Murison R, Bremnes R, Dahl O, Klepp O, Loge JH, Wist E, Dahl AA. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 2008, 64:363-371. 10.1016/j.jpsychores.2008.01.002, 18374735.
5. Andersen JL, Aagaard P. Myosin heavy chain IIX overshoot in human skeletal muscle. Muscle Nerve 2000, 23:1095-1104. 10.1002/1097-4598(200007)23:7<1095::AID-MUS13>3.0.CO;2-O, 10883005.
6. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008, 148:295-309.
7. Bergström J. Muscle electrolytes in man. Scand J Clin Lab Invest 1962, 68:1-110.
8. Mackey AL, Andersen LL, Frandsen U, Suetta C, Sjogaard G. Distribution of myogenic progenitor cells and myonuclei is altered in women with vs. those without chronically painful trapezius muscle. J Appl Physiol 2010, 109:1920-1929. 10.1152/japplphysiol.00789.2010, 20930124.
9. Mackey AL, Kjaer M, Charifi N, Henriksson J, Bojsen-Moller J, Holm L, Kadi F. Assessment of satellite cell number and activity status in human skeletal muscle biopsies. Muscle Nerve 2009, 40:455-465. 10.1002/mus.21369, 19705426.
10. Kvorning T, Andersen M, Brixen K, Schjerling P, Suetta C, Madsen K. Suppression of testosterone does not blunt mRNA expression of myoD, myogenin, IGF, myostatin or androgen receptor post strength training in humans. J Physiol 2007, 578:579-593. 2075150, 17095559.
11. Jespersen JG, Nedergaard A, Reitelseder S, Mikkelsen UR, Dideriksen KJ, Agergaard J, Kreiner F, Pott FC, Schjerling P, Kjaer M. Activated protein synthesis and suppressed protein breakdown signaling in skeletal muscle of critically ill patients. PLoS One 2011, 6:e18090. 10.1371/journal.pone.0018090, 3069050, 21483870.
12. Kues JM, Rothstein JM, Lamb RL. Obtaining reliable measurements of knee extensor torque produced during maximal voluntary contractions: an experimental investigation. Phys Ther 1992, 72:492-501.
13. Bassey EJ, Short AH. A new method for measuring power output in a single leg extension: feasibility, reliability and validity. Eur J Appl Physiol Occup Physiol 1990, 60:385-390. 10.1007/BF00713504, 2369911.
14. Lindegaard B, Hansen T, Hvid T, van HG, Plomgaard P, Ditlevsen S, Gerstoft J, Pedersen BK. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab 2008, 93:3860-3869. 10.1210/jc.2007-2733, 18628529.
15. Lukaski HC. Soft tissue composition and bone mineral status: evaluation by dual-energy X-ray absorptiometry. J Nutr 1993, 123:438-443.
16. St-Onge MP, Wang Z, Horlick M, Wang J, Heymsfield SB. Dual-energy X-ray absorptiometry lean soft tissue hydration: independent contributions of intra- and extracellular water. Am J Physiol Endocrinol Metab 2004, 287:E842-E847. 10.1152/ajpendo.00361.2003, 15238354.
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376. 10.1093/jnci/85.5.365, 8433390.
18. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
19. Galvao DA, Newton RU. Review of exercise intervention studies in cancer patients. J Clin Oncol 2005, 23:899-909. 10.1200/JCO.2005.06.085, 15681536.
20. Murphy EA, Davis JM, Barrilleaux TL, McClellan JL, Steiner JL, Carmichael MD, Pena MM, Hebert JR, Green JE. Benefits of exercise training on breast cancer progression and inflammation in C3(1)SV40Tag mice. Cytokine 2011, 55:274-279. 10.1016/j.cyto.2011.04.007, 21600785.
21. Hojman P, Dethlefsen C, Brandt C, Hansen J, Pedersen L, Pedersen BK. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am J Physiol Endocrinol Metab 2011,
22. Irwin ML, McTiernan A, Manson JE, Thomson CA, Sternfeld B, Stefanick ML, Wactawski-Wende J, Craft L, Lane D, Martin LW, Chlebowski R. Physical activity and survival in postmenopausal women with breast cancer: results from the women's health initiative. Cancer Prev Res (Phila) 2011, 4:522-529.
23. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 2011, 29:726-732. 10.1200/JCO.2010.31.5226, 21205749.
24. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res 2011, 71:3889-3895. 10.1158/0008-5472.CAN-10-3932, 21610110.
25. Schmitz KH, Courneya KS, Matthews C, mark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von GV, Schwartz AL. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010, 42:1409-1426. 10.1249/MSS.0b013e3181e0c112, 20559064.
26. Adamsen L, Quist M, Andersen C, Moller T, Herrstedt J, Kronborg D, Baadsgaard MT, Vistisen K, Midtgaard J, Christiansen B, Stage M, Kronborg MT, Rorth M. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ 2009, 339:b3410. 10.1136/bmj.b3410, 2762035, 19826172.
27. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003, 21:1513-1523. 10.1200/JCO.2003.04.173, 12697875.
28. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse PB, Mulder NH, van den Berg MP, Koops HS, Sleijfer DT. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000, 18:1725-1732.
29. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs 2003, 63:1565-1577. 10.2165/00003495-200363150-00004, 12887263.
30. Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 2009, 10:598-605. 10.1016/S1470-2045(09)70031-2, 19482248.
31. Jones LW, Peppercorn J. Exercise research: early promise warrants further investment. Lancet Oncol 2010, 11:408-410. 10.1016/S1470-2045(10)70094-2, 20434709.
32. Ng AV. The underrecognized role of impaired muscle function in cancer-related fatigue. J Support Oncol 2010, 8:177-178.
33. Bruera E. Cancer-related fatigue: a multidimensional syndrome. J Support Oncol 2010, 8:175-176.
34. Al-Majid S, Waters H. The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise. Biol Res Nurs 2008, 10:7-20. 10.1177/1099800408317345, 18705151.
35. Clarkson PM, Kaufman SA. Should resistance exercise be recommended during breast cancer treatment?. Med Hypotheses 2010,
36. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007, 7:147-156. 10.1124/mi.7.3.6, 17609521.
37. Prado CM, Antoun S, Sawyer MB, Baracos VE. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr Opin Clin Nutr Metab Care 2011, 14:250-254. 10.1097/MCO.0b013e3283455d45, 21415735.
38. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 2010, 28:1054-1060. 10.1200/JCO.2009.24.9730, 20085939.
39. Weber MA, Krakowski-Roosen H, Schroder L, Kinscherf R, Krix M, Kopp-Schneider A, Essig M, Bachert P, Kauczor HU, Hildebrandt W. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol 2009, 48:116-124. 10.1080/02841860802130001, 18607877.
40. Smuder AJ, Kavazis AN, Min K, Powers SK. Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle. J Appl Physiol 2011,
41. van NK, van HA, Argiles JM, van TS, Arts K, Gorselink M, Laviano A, Kegler D, Haagsman HP, van der Beek EM. Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br J Cancer 2009, 100:311-314. 10.1038/sj.bjc.6604858, 2634729, 19165199.
42. Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, Reid MB. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J Appl Physiol 2009, 107:1935-1942. 10.1152/japplphysiol.00776.2009, 2793196, 19779154.
43. Smuder AJ, Kavazis AN, Min K, Powers SK. Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. J Appl Physiol 2011,
44. Jones LW, Douglas PS, Eves ND, Marcom PK, Kraus WE, Herndon JE, Inman BA, Allen JD, Peppercorn J. Rationale and design of the Exercise Intensity Trial (EXCITE): a randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. BMC Cancer 2010, 10:531. 10.1186/1471-2407-10-531, 2965727, 20925920.
45. Jones LW, Eves ND, Kraus WE, Potti A, Crawford J, Blumenthal JA, Peterson BL, Douglas PS. The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. BMC Cancer 2010, 10:155. 10.1186/1471-2407-10-155, 2888787, 20409311.
46. Lackner JE, Mark I, Schatzl G, Marberger M, Kratzik C. Hypogonadism and androgen deficiency symptoms in testicular cancer survivors. Urology 2007, 69:754-758. 10.1016/j.urology.2007.01.002, 17445664.
47. Brennemann W, Stoffel-Wagner B, Helmers A, Mezger J, Jager N, Klingmuller D. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol 1997, 158:844-850. 10.1016/S0022-5347(01)64333-7, 9258096.
48. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001, 91:1297-1303. 10.1002/1097-0142(20010401)91:7<1297::AID-CNCR1132>3.0.CO;2-Z, 11283930.
49. Kvorning T, Andersen M, Brixen K, Madsen K. Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study. Am J Physiol Endocrinol Metab 2006, 291:E1325-E1332. 10.1152/ajpendo.00143.2006, 16868226.
50. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D'Angelo ME. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009, 27:344-351.
51. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JK, Lane K, Yasui Y, McKenzie DC. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 2007, 25:4396-4404. 10.1200/JCO.2006.08.2024, 17785708.
52. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003, 21:1653-1659. 10.1200/JCO.2003.09.534, 12721238.
53. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007, 13:3264-3268. 10.1158/1078-0432.CCR-06-3067, 17545532.
54. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009, 15:2920-2926. 10.1158/1078-0432.CCR-08-2242, 19351764.